Click to Share
 
 
  1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution
Filter News
Show All Results
News By Country
News By Tag
Immune Response Biopharma Remove


July 2014
Th We Tu Mo Su Sa Fr
31 30 29 28 27 26 25

immune response biopharma Press Releases

  + XML/RSS  



By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. to Seek FDA Approval for Expanded Use of Blockbuster HIV/AIDS Vaccine REMUNE for HIV/AIDS Monotherapy as it produces huge green shoots of CD8+ T cells Killer White Blood Cells

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. Posts Record 1st Half 2014 Results Blockbuster HIV/AIDS Vaccine REMUNE Set to Become First HIV/AIDS Vaccine to File for FDA BLA Approval & Come to Market.

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. to Seek FDA Breakthrough Designation of REMUNE HIV/AIDS Vaccine for Pediatric Treatment & Plans Phase II Pediatric Study.

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. to Seek BLA Approval of REMUNE with EMA & Enter the Eurozone with Expansion of HIV Vaccine Marketing Authorization

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. IR103 Phase II Study Results CTN 203 or IR103-111 REMUNEX Provides Maximum Effect in Patients Treated with REMUNE + Amplivax HIV/AIDS Vaccine.

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. to Seek Emergency Approval of REMUNE in Thailand & Begin Stockpiling HIV/AIDS Vaccine

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. Announces New ZORCELL Psoriasis Vaccine Phase IIb Study Safety & Efficacy 350 Patients ZORCELL + Methotrexate 6 Months Study.

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. Adopts Shareholder Rights Plan & Poison Pill Anti-Takeover Provision

All Press Releases

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. to Seek FDA Approval for Expanded Use of Blockbuster HIV/AIDS Vaccine REMUNE for HIV/AIDS Monotherapy as it produces huge green shoots of CD8+ T cells Killer White Blood Cells

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. Posts Record 1st Half 2014 Results Blockbuster HIV/AIDS Vaccine REMUNE Set to Become First HIV/AIDS Vaccine to File for FDA BLA Approval & Come to Market.

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. Selects Seppic to Supply Incomplete Freund’s Adjuvants (IFA) for REMUNE HIV/AIDS Vaccine Commercialization & Pipeline

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. to Seek FDA Breakthrough Designation of REMUNE HIV/AIDS Vaccine for Pediatric Treatment & Plans Phase II Pediatric Study.

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. to Seek Fast Track & Orphan Designation of NeuroVax for SPMS to Expand Novel use of MS Vaccine Treatment

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. Posts 1st Half 2013 Results & 2nd Half 2013 Guidance on Partnering

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. to Seek BLA Approval of REMUNE with EMA & Enter the Eurozone with Expansion of HIV Vaccine Marketing Authorization

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc., has notified the MCC of South Africa that IRBP will Seek Emergency Approval of REMUNE in S.A. as well begin stockpiling & manufacturing the HIV/AIDS vaccine once we have secured a corporate partner in the region.

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. IR103 Phase II Study Results CTN 203 or IR103-111 REMUNEX Provides Maximum Effect in Patients Treated with REMUNE + Amplivax HIV/AIDS Vaccine.

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. Sets Pricing of REMUNE Vaccine in Thailand Between $75-100 Per Dose for Emergency Approval of HIV/AIDS Vaccine

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. to Seek Emergency Approval of REMUNE in Thailand & Begin Stockpiling HIV/AIDS Vaccine

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. to Seek Orphan Designation of NeuroVax for Pediatric Multiple Sclerosis to Expand Use of Novel Vaccine Treatment. Immune Response BioPharma, Inc.

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. Selects the American Stock Transfer & Trust Company as Transfer Agent of Record.

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. Posts 2nd Half 2012 & Full Year Results

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. Files for Orphan Designation of REMUNE for Pediatric HIV/AIDS

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. Announces New ZORCELL Psoriasis Vaccine Phase IIb Study Safety & Efficacy 350 Patients ZORCELL + Methotrexate 6 Months Study.

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. Adopts Shareholder Rights Plan & Poison Pill Anti-Takeover Provision

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. Publishes Phase III Full 806 Study Results, REMUNE Very Effective Demonstrating 0.7% HIV Progression vs 6% Estimated Rate & Subgroup Median Virologic Failure Delayed by 20 Weeks In REMUNE Group.

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. Provides Business Update Sees Blockbuster MS Drug NeuroVax the Gold Standard of Care for MS and a Partnership by the end of Q1 2013

By Immune Response BioPharma, Inc.
REMUNE Effectiveness Extends Years After Inoculation REMUNE Injected Patient Has 2 Healthy HIV Free Children Proving the Vaccine has Strong Immune Responses a Decade Later

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. Sees First Year REMUNE Sales North of $1 Billion Dollars

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. Review of Blockbuster RA Vaccine RAVAX Phase 2B 340 Patient Study Results Demonstrated a 50% Improvement in Patients Vaccinated with RAVAX.

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. Provides Blockbuster RAVAX Phase III Study in RA Update With Inadequate Response to Humira or Enbrel now Available at www.immuneresponse.net

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. Posts 1st Half 2012 Results Highlights include IRBP Granted U.S. Patent 8,053,197 for Auto-Immune Diseases & Plans for a Phase 2B NeuroVax Study and a Phase 3 RAVAX Study for RA.

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. Terminates Blockbuster MS Drug NeuroVax Partnership Discusions With GSK

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. announced today that it has received United States Patent Number 8,053,197 expanding coverage relating to its immune-based therapy for Treatment of Auto-Immune Diseases.



Page:
  • 1

Page updated every 10 minutes


  1. SiteMap
  2. Contact PRLog
  3. Privacy Policy
  4. Terms of Service
  5. Copyright Notice
  6. About
  7. Advertise
Like PRLog?
9K2K1K
Click to Share